<DOC>
	<DOCNO>NCT00574288</DOCNO>
	<brief_summary>Establishment safety profile HuMax-CD38 give monotherapy participant multiple myeloma relapse refractory least 2 different cytoreductive therapy without establish treatment option .</brief_summary>
	<brief_title>Daratumumab ( HuMaxÂ®-CD38 ) Safety Study Multiple Myeloma</brief_title>
	<detailed_description>This study conduct two part . In part I , participant enrol cohort increase dose level . Participant safety efficacy part I determine dos use Part II . In part II participant enrol one two sequential treatment arm use two dos define part 1 study . Part II 5 cohort , 3 8 milligram per kilogram ( mg/kg ) 2 16 mg/kg . Part I last cohort Part II dose Phase 1/ 2 drug product . The last cohort Part II dose Phase 3 drug product . Both Part I Part II open-label/unmasked .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Daratumumab</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion criterion Diagnosis multiple myeloma ( MM ) require systemic therapy Age great equal ( &gt; = ) 18 year Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Life expectancy great ( &gt; ) 3 month Relapsed refractory two different prior therapy Signed Informed consent Exclusion criterion Plasma cell leukemia define plasma cell count &gt; 2000/millimeter^3 ( mm^3 ) Known amyloidosis Participants previously receive allogeneic stem cell transplant Sensory motor neuropathy &gt; = grade 3 Past current malignancy Chronic ongoing active infectious disease Clinically significant cardiac disease Significant concurrent , uncontrolled medical condition include , limited , renal ( except relate MM ) , hepatic , hematological except MM , gastrointestinal , endocrine , pulmonary , neurological , cerebral psychiatric disease A baseline QT interval correct Fridericia 's formula &gt; 470 millisecond ( msec ) female participant &gt; 450 msec male participant complete leave bundle branch block ( define QRS interval &gt; = 120 msec leave bundle branch block form ) Hypokalemia Clinical sign meningeal involvement MM Known severe chronic obstructive pulmonary disease asthma define forced expiratory volume 1 second ( FEV1 ) less ( &lt; ) 60 percentage ( % ) expect History significant cerebrovascular disease Known Human Immunodeficiency Virus seropositivity Positive serology hepatitis B Screening laboratory value Concomitant corticosteroid Other chemotherapy may active myeloma within 3 week prior Visit 2 ( Part 1 ) first dose daratumumab ( Part 2 ) . However , corticosteroid myeloma ( le 4day course ) could administer within 1 week Visit 2 ( Part 1 ) first dose daratumumab ( Part 2 ) Known hypersensitivity component investigational product severe allergic anaphylactic reaction humanize product Participants receive treatment nonmarket drug substance within 4 week first dose daratumumab Current participation interventional clinical trial Participants know suspect able comply trial protocol ( example , due alcoholism , drug dependency , psychological disorder ) Breastfeeding woman woman positive pregnancy test Screening Women childbearing potential willing use adequate contraception , define hormonal birth control intrauterine device , trial 1 year last dose daratumumab . For participant United States , use doublebarrier method also consider adequate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Daratumumab</keyword>
	<keyword>Safety</keyword>
	<keyword>HuMax-CD38</keyword>
	<keyword>Dose-escalation</keyword>
</DOC>